Compared to LOXL2 knockdown, systemic LOXL2 inhibition by ellagic acid treatment was more effective at reducing tumor growth and did not exhibit increased intratumoral collagen nor increased LAIR1+CD8+ TILs when combined with anti-PD-L1, which suggests that the source of collagen in tumors can originate from multiple cell types (e.g., cancer-associated fibroblasts) in addition to cancer cells50. The gene discussed is CD274; the disease is neoplasm.